Enzon Pharmaceuticals, INC 10-Q quarterly reports

Viskase Holdings, Inc. reported a net loss of $5.13 million for the second quarter of 2026, with net sales decreasing by 7.3% year-over-year, while facing substantial doubt regarding its ability to continue as a going concern.

Viskase Holdings, Inc. reported a net loss of $6.7 million for the first quarter ended March 31, 2026, with net sales decreasing 8.1% year-over-year, impacted by volume declines and restructuring efforts.

Enzon Pharmaceuticals reported a net loss for Q3 2025 and the nine months ended September 30, 2025, while announcing an amendment to its merger agreement with Viskase Companies, Inc., extending the closing date and adjusting ownership.

Enzon Pharmaceuticals reported a net loss for Q2 2025, with cash declining, and detailed significant shareholder dilution and NOL limitations from its pending merger with Viskase.

Enzon Pharmaceuticals, a public company acquisition vehicle, reported its Q1 2025 financial results, showing a net loss and ongoing efforts to identify and pursue acquisition opportunities.

Enzon Pharmaceuticals reported its financial results for the third quarter of 2024, highlighting a net loss available to common stockholders of $277,000 and continued efforts to identify a suitable acquisition target.

Enzon Pharmaceuticals reported a net loss available to common shareholders of $466,000 for the first six months of 2024, while continuing its search for an acquisition target.

Enzon Pharmaceuticals reported a net loss available to common shareholders of $211,000 for the first quarter of 2024, while continuing its search for an acquisition target to utilize its net operating loss carryforwards.